Immuneering To Initiate Phase 3 Atebimetinib Trial In Pancreatic Cancer In Mid-2026
I'm PortAI, I can summarize articles.
Immuneering Corp. announced plans to initiate a Phase 3 trial of Atebimetinib for metastatic pancreatic cancer in mid-2026. The trial, named MAPKeeper 301, will involve 510 patients and compare Atebimetinib with modified gemcitabine and nab-paclitaxel against the standard treatment. The FDA and European Medicines Agency have aligned on the trial's design and endpoints. Immuneering will also update on Phase 2a trial results soon. Additionally, Immuneering will join the Nasdaq Biotechnology Index in December 2025.
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: rttnews The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments